News
News Center
From "Stem Cell Research" to "Stem Cell Pharmaceuticals" —— The pharmaceutical hub introduces a world-class stem cell production facility.
来源：Zhongguancun Science Park Daxing Biopharmaceutical Industry Base Website
2018-09-18
As a leading Chinese enterprise in traditional Chinese medicine pharmaceuticals, Jiuzhi堂 leverages its strong expertise in the TCM industry while capitalizing on global advancements in stem cell technology to make a strategic move into the regenerative medicine sector. To this end, the company has established a subsidiary—Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.—which is now based at the Zhongguancun Medical Device Park, a premier biomedical hub. The new company will focus on stem cell research and development, clinical applications, and commercialization efforts.
As a leading Chinese enterprise in traditional Chinese medicine pharmaceuticals, Jiuzhi堂 leverages its strong expertise in the TCM industry while capitalizing on global advancements in stem cell technology to make a strategic move into the regenerative medicine sector. To this end, the company has established a subsidiary—Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.—which is now based at the Zhongguancun Medical Device Park, a premier biomedical hub. The new company will focus on stem cell research and development, clinical applications, and commercialization efforts.
At this forum, Jiuzhitang Maker, the fund initiated and established by Jiuzhitang, signed an investment agreement with Stemedica Cell Technologies Inc., a U.S.-based company based in San Diego’s Biotech Valley—San Diego—which boasts over a decade of experience in stem cell research, development, manufacturing, and marketing. According to the agreement, Jiuzhitang Maker (Beijing) Cell Technologies Co., Ltd. (hereafter referred to as Jiuzhitang Maker) will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from a world-class global stem cell enterprise. Over the next 3 to 5 years, the company plans to build a commercial-grade stem cell production facility meeting both U.S. and EU cGMP standards at the Beijing Daxing Biopharmaceutical Industry Base. This facility will focus on manufacturing human bone marrow-derived mesenchymal stem cells and neural stem cells, covering a total area of 4,500 square meters and is expected to become operational by 2019.
In his speech at the event, Tian Dexiang from the Pharmaceutical Base Management Committee emphasized that this academic exchange and project collaboration between the pharmaceutical base and Jiuzhitang will undoubtedly lead to mutually beneficial cooperation, further enhancing the park's business environment. This initiative marks the introduction of another stem-cell project to the pharmaceutical base, following the successful partnership with Jiansheng Bio. The pharmaceutical base remains committed to leveraging the innovative capabilities and resource advantages of its resident companies, striving to integrate China’s traditional medicine with cutting-edge stem-cell biotechnology. By doing so, the base aims to forge a pioneering path for innovation among time-honored Chinese pharmaceutical enterprises, driving the brand influence and overall strength of the park to new heights—and propelling iconic traditional Chinese medicine companies one significant step closer to becoming leaders in pharmaceutical innovation.
Going forward, the biopharmaceutical base will align with Beijing’s “Three Cities and One Zone” industrial development strategy by providing comprehensive support services for companies looking to establish themselves there. It will remain committed to an innovation-driven approach while fully leveraging a series of talent and biopharmaceutical industry support policies introduced by Daxing District. In the future, the pharmaceutical base will also launch multiple international center clinical trials, further advancing the development of stem-cell-based drug technologies. Additionally, it will continue to enhance its end-to-end biopharmaceutical industry service platform, strengthening its position as a world-class, domestically leading biopharmaceutical park under the "China Pharmaceutical Valley" brand. Ultimately, the base aims to evolve into an integrated "health-focused new city" that seamlessly combines research, production, commerce, exhibitions, and healthcare services.
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy